Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649 Meeting Abstract
| Authors: | Shitara, K.; Janjigian, Y. Y.; Moehler, M. H.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, C. A. S.; Liu, T.; Tehfe, M.; Elimova, E.; Soleymani, S.; Lei, M.; Kondo, K.; Li, M.; Ajani, J. A. |
| Abstract Title: | Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649 |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900234 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.240 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 240 -- Meeting was conducted online as well as in person -- Source: Wos |
